Yang et al.’s study and our own work have uncovered novel DNMT inhibition-independent action mechanisms of zebularine and have shed new light on zebularine’s potential as a treatment for clinical colorectal cancer and hepatocellular cancer, respectively. This evidence concerns the gene DNMT1 and hepatocellular carcinoma.